Asia Beat: Blazing the biosimilar trail the Korean way
This article was originally published in Scrip
The first approval worldwide of a monoclonal antibody under formal biosimilar guidelines - infliximab in South Korea in late July - has whipped up industry interest in the country's biosimilars capabilities, at least if the hits on Scrip's news article are anything to go by.
You may also be interested in...
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.